Andere Sprachen Immunic, Inc.

Aktien

A2PHD4

US4525EP1011

IMUX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 06.05.2024			% 5 Tage	% 1. Jan.
1.34 ^USD	-2.19%		+8.94%	-10.67%

30.04.	Immunic gibt die Veröffentlichung erweiterter Daten aus der Phase 2 EMPhASIS-Studie mit Vidofludimus Calcium bei schubförmiger Multipler Sklerose in der Fachzeitschrift Neurology® Neuroimmunology & Neuroinflammation bekannt	CI
09.04.	Transcript : Immunic, Inc. - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immunic to Participate in Investor and Scientific Conferences in May	06.05.
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal	01.05.
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation	01.05.
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update	01.05.
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	30.04.
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role	29.04.
Immunic to Host MS R&D Day and Participate in Investor Conferences in April	04.04.
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	21.03.
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month	21.03.
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy	21.03.
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States	20.03.
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024	08.03.
Immunic to Participate in Investor and Scientific Conferences in March	07.03.
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024	29.02.
Immunic reports successful 2023 and prepares for key 2025 milestones	22.02.
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update	22.02.
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update	15.02.
Immunic to Participate in Investor and Scientific Conferences in February	01.02.
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	05.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immunic, Inc.

Aktien

A2PHD4

US4525EP1011

IMUX

Andere Sprachen

Filter